Pneumonia Vaccines Market in Europe is expected to register a CAGR of 4.5% during the forecast period (2019-2025) - KBV Research

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

According to a new report Europe Pneumonia Vaccines Market, published by KBV research, the Europe Pneumonia Vaccines Market would witness market growth of 4.5% CAGR during the forecast period (2019-2025).

The Germany market dominated the Europe Prevnar 13 Market by Region in 2018, growing at a CAGR of 2.4 % during the forecast period. The UK market is expected to witness a CAGR of 2.8% during (2019 - 2025). Additionally, The France market is expected to witness a CAGR of 4.3% during (2019 - 2025).

The Distribution Partner Companies market dominated the Europe Pneumonia Vaccines Market by Distribution Channel in 2018, growing at a CAGR of 3.7 % during the forecast period. The Non-Governmental Organizations (NGO) market is expected to witness a CAGR of 5.4% during (2019 - 2025).

The Private sector market dominated the France Pneumonia Vaccines Market by Sector in 2018, thereby, achieving a market value of $270.2 million by 2025, growing at a CAGR of 4.3 % during the forecast period. The Public sector market is expected to witness highest CAGR of 8.1% during (2019 - 2025).

Full Report: https://www.kbvresearch.com/europe-pneumonia-vaccines-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Glaxosmithkline Plc. (GSK), LG Corporation, Panacea Biotec Limited, Pfizer, Inc., Pnuvax Incorporated, Poonawalla Investments & Industries Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., SK Holdings Co., Ltd., Walvax Biotechnology Co., Ltd. and MERCK & CO., Inc.